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 Abstract 
Regardless of their tissue of origin, multipotent mesenchymal stromal cells (MSCs) are 
commonly expanded in vitro for several population doublings, in order to achieve a sufficient 
number of cells for therapy. Prolonged MSC expansion has shown to result in phenotypical, 
morphological and gene expression changes in MSCs, which ultimately lead to the state of 
senescence. The presence of senescent cells in therapeutic MSC batches is undesirable, as it 
reduces their viability, differentiation potential and trophic capabilities. Additionally, 
senescent cells acquire senescence-activated secretory phenotype, which may not only induce 
apoptosis in the neighbouring host cells following MSC transplantation, but also trigger local 
inflammatory reactions. This review outlines the current and promising new methodologies 
for the identification of senescent cells in MSC cultures, with a particular emphasis on non-
destructive and label-free methodologies. Technologies allowing identification of individual 
senescent cells, based on new surface markers, offer potential advantage for targeted 
senescent cell removal using new-generation senolytic agents, and subsequent production of 
therapeutic MSC batches fully devoid of senescent cells. Methods or a combination of 
methods that are non-destructive and label-free, for example involving cell size and 
spectroscopic measurements, could be the best way forward as they do not modify the cells of 
interest thus maximising the final output of therapeutic-grade MSC cultures. The further 
incorporation of machine learning methods has also recently shown promise in facilitating, 
automating and enhancing the analysis of these measured data.  
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Introduction 
Multipotent mesenchymal stromal cells (MSCs) have the ability to expand in culture, and 
with appropriate culture conditions, differentiate into at least three mesodermal cell lineages: 
osteocytes, chondrocytes and adipocytes [1]. In recent years, MSCs have attracted significant 
research and clinical interest due to their multipotent differentiation potential, trophic 
functions and applications in cell and gene therapy [2]. Due to their high proliferative 
capacity in vitro and the low risk of in vivo tumour formation in transplanted cells, MSCs 
have been employed in cell based therapy for various diseases including graft-versus-host 
disease, multiple sclerosis, myocardial infarction, liver failure and rejection after liver 
transplant [3, 4]. Moreover, cultured MSCs have been extensively used in tissue engineering 
applications to repair large articular cartilage and bone defects [5] or as a suitable vehicle for 
transplantation in both cell and gene therapy for the central nervous system [6]. However, the 
clinical outcomes of MSC transplantation remain variable, and this could be in part explained 
by difficulties in controlling both host responses and the fate of transplanted cells [7].  
    The variable outcomes may also be due to different MSC tissue sources used, such as bone 
marrow, adipose tissue, periosteum, synovium, umbilical cord, placenta, and skin [8, 9]. 
Furthermore, MSCs can be isolated and expanded through different procedures, with the use 
of different media, seeding densities and oxygen levels [10]. To minimise these 
inconsistencies, the International Society for Cellular Therapy (ISCT) issued a position 
statement in 2006 to propose the minimal criteria to define human MSCs [11]. While these 
criteria are useful for describing MSC purity in growing adherent cultures, additional potency 
assays are needed in order to predict clinically important factors such as MSC differentiation 
and immunomodulation capabilities, as well as growth factor production [10, 12].  
    It is well-documented that human MSCs (hMSCs) lose their differentiation potential after 
prolonged culture expansion in vitro [13, 14] and that the cells from late, pre-senescent 
passages  may not be able to differentiate at all [2, 15, 16, 17 ]. Additionally, large numbers 
of senescent cells in MSC cultures negatively impact on cultures¶ immunomodulatory and 
homing abilities [18-20], which in turn may lead to lessened efficacy following implantation 
[16, 19]. Therefore, the assessment of MSC cultures for the presence of senescent cells may 
become one of the critical quality attributes (CQAs) [21] helping to ensure the best MSC 
product quality. This review article presents current methods for MSC senescence analysis, 
and highlights promising new methods that are non-destructive and label-free with potential 
to become on-line  [22] quality control tests [23] for therapeutic MSC products. 
 
Replicative and stress-induced senescence in MSC cultures: main features 
Cellular senescence is generally defined as the essentially irreversible arrest of cell 
proliferation [24]. Replicative senescence refers to irreversible growth arrest of human 
diploid cell strains after extensive serial passaging in culture [25]. MSC cultures are 
heterogeneous in relation to cell cycle progression of their individual cells [26], and as 
passage number increases, the relative proportions of fast-dividing highly-proliferative cells 
gradually decline, while slow dividing less-proliferative cells increase [2]. Ultimately, very 
late passage cultures are primarily composed of large, non-proliferative, senescent cells.  
    Besides replicative senescence [27], MSC senescence can also be stress induced, linked to 
the free radical theory of aging [28]. Free radicals/reactive oxygen species (ROS) are unstable 
molecules that have an unpaired electron, and their accumulation leads to oxidative stress, 
DNA damage, protein damage and mitochondrial dysfunction. Oxidative stress in normal 
cells is counter-balanced by anti-oxidants such as Superoxide Dismutase (SOD), catalase, 
peroxiredoxin, thioredoxin and glutathione systems. However, in senescent MSCs SOD 
activity is reduced, while ROS production is increased [2, 29, 30]. Persistent oxidative stress 
and DNA damage response can then initiate growth arrest and activation of p38MAPK, 
PI3K/AKT/mTOR/FOXO3 and p53 signalling pathways. Both p53 and p38MAPK pathways 
have been reported to be responsible for an irreversible cell cycle arrest in human MSCs 
exposed to exogenous ROS treatment, and the pharmacological inhibition of p38MAPK was 
sufficient to restore normal mitochondrial function and rescue MSC proliferation [31]. 
Therefore, endogenous ROS accumulation plays a key role in stress induced MSC senescence 
[2, 24, 29].  
     Mitochondrial dysfunction and continuous oxidative stress severely affect MSC 
metabolism. Unlike mild or transient oxidative stress, which enhances the proteasome 
activity, severe oxidative stress appears to inhibit it [32]. Suppression of proteasomes, which 
act to degrade damaged proteins (i.e. oxidized, misfolded and cross-linked), further 
exacerbates senescent cell phenotype [33]. With regards to lipid metabolism, senescent 
fibroblasts have been shown to possess decreased lipid synthesis and increased fatty acid 
oxidation, consistent with active mitochondrial oxidation in senescent cells [34]. Importantly, 
energy metabolism has recently emerged as an important determinant of the stem cell fate 
[35]. In their undifferentiated state, anaerobic glycolysis meets the stem cell need for 
proliferation, but they become more dependent on glucose oxidation during differentiation 
[36]. In one study, senescent MSCs did not appear to utilise anaerobic glycolysis and instead, 
produced ATP primarily via oxidative phosphorylation, a metabolic activity more consistent 
with differentiated cells [37]. However, a more recent study has shown that senescence-
associated changes in MSCs included down-regulation of nicotinamide ribonucleotide and 
up-regulation of orotic acid, and reflected the metabolic switch from oxidative to glycolytic 
pathways, possibly to avoid further damage by ROS [38]. 
 
The exact molecular mechanism governing replicative MSC senescence is not clearly 
known. Telomeres have been associated with the molecular machinery for cell replicative 
lifespan, and their shortening is indicative of the cell aging process [39, 40]. Telomere 
shortening, and the loss of telomeric DNA through subsequent generations, is linked with 
replicative senescence and was previously reported in human fibroblasts, endothelial cells, 
myoblasts as well as MSCs [41-43]. However, modification to the telomeric structure is 
unlikely to be the only cause of MSC senescence following culture. As mentioned, DNA 
damage and oxidative stress are likely to be other contributory factors [29, 44] particularly as 
MSCs are commonly grown under supra-physiological oxygen levels [45]. 
Wagner et al. carried out comprehensive analysis of the changes in morphology, 
immunophenotype and differentiation capacity of MSCs serially-passaged in culture [15]. 
Having observed gradual changes in the global gene expression and miRNA expression 
throughout MSC passages, the authors concluded that senescence-like changes in MSCs were 
not only restricted to senescent passages, but were continuously acquired from the start of in 
vitro expansion [15]. Since senescence is a distinct cell state, while changes in gene and 
protein expression were observed gradually at the culture (cell population) levels, their data 
indicated a gradual accumulation of senescent cells from early- to late-passage MSC cultures. 
Therefore identifying senescent cells even in early MSC cultures may be of a significant 
scientific and therapeutic value. 
In addition to growth arrest and widespread changes in chromatin organization and gene 
expression, senescent cells are characterised by a so-called senescence-associated secretory 
phenotype (SASP) [24]. The SASP secretome consist of growth factors and cytokines 
including interleukin-1 (IL-1), IL-3, IL-4, IL-6, IL-8, epidermal growth factor), hepatocyte 
growth factor, insulin growth factor, platelet derived growth factor, TGF-ȕand vascular 
endothelial growth factor (VEGF) [46] that amongst their other roles, regulate MSCs 
proliferation in culture and are crucial to MSC senescence as well [2]. Senescent MSC 
secretome can induce senescence and apoptosis in other cells [47], as well an inflammatory 
responses in neighbouring cells [16, 27]. Critically, transplantation of even small numbers of 
senescent cells can cause age-related disease phenotypes, such as osteoarthritis, as shown 
recently by Xu et al. [48]. 
In MSC mediated therapies, where large-scale MSC expansion in culture is often required 
prior to transplantation, the impact of senescent cells accumulation on MSC biological 
activities remains poorly understood. As mentioned above, enlarged and irregular cell shape 
and shortened telomere lengths of senescent cells in MSC cultures [15, 43] may affect their in 
vivo trafficking and proliferation. Senescent cell accumulation is likely to be responsible for a 
decrease in the overall multipotent differentiation ability of long term expanded MSCs [26, 
49]. Finally, senescent cells SASP can accelerate ageing [48] or induce apoptosis [47] in the 
neighbouring cells. Thus, having a direct method for identification, quantification and 
ultimately, removal of senescent cells in MSC cultures would have a significant value for 
ensuring the quality of MSCs intended for clinical applications.  
    One of the earliest, indirect methods of assessing MSC senescence is the colony-forming 
units-fibroblast (CFU-f) assay [50, 51]. The measured clonogenic cell number indicates cells 
that remain viable and proliferative enough to form visible colonies, and therefore gives an 
indirect indication (by subtraction) as to the proportions of senescent (i.e. non-proliferative) 
and poorly-proliferative cells. DiGirolamo et al. were first to use a CFU-f assay to study 
MSC cultures isolated from iliac crest bone marrow aspirates of normal volunteers. Their 
major findings were that the number of CFU-fs declined as MSC were expanded in culture, 
showing that the colony forming efficiency dropped to nearly 1% at passage 7 as compared to 
25% at passage 2 [52]. As the cultures approached senescence, they retained the ability to 
differentiate into osteoblasts, but failed to differentiate into adipocytes. This has been 
confirmed in other independent studies [17, 43, 53]. Similarly, Schellenberg et al. showed 
more recently that in MSCs isolated from lipoaspirates, 18.4% of passage 1 cells generated 
CFU-f colonies [26]. This dropped significantly over subsequent passages, and after 10 
passages, only 5% of the cells generated CFU-fs. Eventually, after 20 passages, colony 
formation was rarely observed [26]. These data not only indicated that MSCs were 
heterogeneous, but also confirmed the notion of replicative senescence occurring in both 
bone marrow and adipose derived MSCs.  
Despite this assay being useful for the identification of senescent MSC passages (those 
containing no colony forming cells), it notably measures highly-proliferative, as opposed to 
senescent cells, and is time consuming and highly subjective. In a recent study by Zorin et al., 
the group confirmed that cells that tested positive for senescence were the highest in small 
diffuse colonies of human skin fibroblast cultures, and they originated from the cells with the 
least proliferative potential [54]. However, counting such small colonies as representative of 
pre-senescent cells remains inaccurate and very subjective. Thus, more accurate, quantitative 
and rapid characterisation techniques have been developed for better identifying individual 
senescent cells with a potential for their later removal in MSC cultures.  
    In the following sections, we discuss the current standards for characterizing senescent 
passages, or senescent cells in MSC cultures, as well as highlight promising new methods 
that employ specific markers in senescence measurements, summarized in Table 1. We 
propose that optimal methods of MSC senescence characterization should be quantitative, 
rapid, allow high-throughput, cost-effective and ideally, label-free and non-destructive.  
 
 
Current Standards 
 
Senescence-associated E-galactosidase activity (SA-E-gal) measurements 
The detection of SA-E-gal activity is the most contemporary standard for the evaluation of 
cell senescence. 7KHKXPDQDFLGȕ-D-JDODFWRVLGDVHȕ-Gal) is a eukaryotic hydrolase 
ORFDOL]HGLQWKHO\VRVRPHWKDWFDWDO\VHVWKHK\GURO\VLVRIWHUPLQDOȕ-linked galactose residues 
in glycoproteins and glycolipids [55]. Under normal growth conditions, the enzymatic 
activity can be detected in cells at the optimal lysosomal pH 4.0. Senescence-associated beta-
galactosidase (SA-E-Gal) is defined as beta-galactosidase activity detectable at the less 
favourable pH conditions (pH 6.0), most likely due to increase in lysosomal mass in 
senescent cells [56], as well as the accumulation of increased levels of GLB1 (gene encoding 
lysosomal E-D-galactosidase) mRNA and protein [57] in senescent cells. Currently, there are 
two types of SA-E-gal activity measuring methods: cytochemical/histochemical or 
fluorescence-based. The cytochemical method requires incubation of fixed cells with the 
chromogenic E-galactosidase substrate X-gal at pH 6.0. After staining, a blue colour develops 
in senescent cells within 2 hours, and the proportion of cells positive for SA-E-gal (i.e. 
senescent cells) can be determined by simply counting the number of blue cells in the total 
population. If shielded from light, the blue staining is relatively stable and remains detectable 
in fixed specimens for several months [58]. 
    The cytochemical method is time consuming, subjective and prone to operator errors. 
There may be false-positive results related to MSC state of confluency [58, 59]. Importantly, 
the degree of blue colour (representing the actual enzyme activity) is not standardized and 
can be biased when interpreted by different users. To overcome these drawbacks, more recent 
studies have proposed new programs and algorithms to implement automatic counting of 
senescent cells, which potentially offer unbiased and reproducible results when compared to 
manual counting [60].  
    For fluorescence detection of SA-E-gal activity, cells are incubated with C12FDG, a E-
galactosidase substrate that becomes fluorescent after cleavage by the enzyme. With this 
method, differences in SA-E-gal activity within and between cell populations could be more 
accurately evaluated [61]. In the study reported by Noppe et al. using cultured fibroblasts, the 
flow cytometric method provided measurements of SA-E-gal activity on a continuous 
fluorescence scale rather than strictly classifying positive or negative for SA-E-gal activity 
fractions. This was consistent with the suggestion made by Wagner et al., that senescent cell 
accumulation in MSC cultures is a continuous process rather than rapid event [15]. The flow 
cytometric method has the advantage of measuring SA-E-gal activity of living cells, whereas 
cytochemical methods are performed on fixed cells [61]. To maintain the internal pH of 
lysosomes in living cells at ~pH 6.0, bafilomycin A1 is commonly chosen rather than another 
more toxic lysosomal inhibitor chloroquine [58, 61]. Both agents promote lysosomal 
alkalization, acting as strong inhibitors of the vacuolar-type H(+)-ATPase that helps 
lysosomes maintain an acidic lumen [62].  
    As the fluorescence detection of SA-E-gal activity has been so far performed mostly on 
fibroblasts, method optimization is still required for characterizing senescent MSCs. This 
includes optimisation of C12FDG concentration and staining time, MSC staining conditions 
(in a monolayer or in suspension), as weOODVµILQH-WXQLQJ¶IORZF\WRPHWU\acquisition settings 
(for example, the number of acquired cells or the use of dead cell discrimination).  As in the 
cytochemical method, results are highly sensitive to assay conditions and consequently it is 
possible that the fluorescent output is too weak for clear distinction between highly-
proliferative and senescent cells in the MSC culture. Additionally, it remains to be a 
destructive method. However, as flow cytometry is a multiparameter technique, this can be 
combined with cell size measurements for clearer classification, as recently shown in Bertolo 
et al. [63] and elaborated further in the Promising New Methods section.  
 
Telomere Length Measurements 
Telomeres are repetitive nucleotide sequences at the end of the linear chromosomes that play 
a critical role in facilitating complete chromosome replication. In somatic cells, such as 
fibroblasts, telomeres shorten during each cell division till they reach a critical length at 
replicative senescence [64, 65]. As a result, mean telomere restriction fragment (mTRF) 
length analysis has been used to estimate the replicative history and predict senescence in 
MSC cultures [66]. Baxter et al. investigated the mTRFs of hMSCs from two donor groups 
aged 0-18 and 59-75 years, and demonstrated a clear correlation between hMSC remaining 
proliferation potential and telomere length, both in culture and with donor age [43]. In this 
study, the telomere length indicative of the state of senescence was proposed to be 10kb [43]. 
Oja et al. similarly found that the mean telomere length was shortened at a constant rate 
during MSC culture, however, this was from 8.2±0.3 kbp at p1 to 6.08±0.6 kbp at senescence 
[67]. Thus, there is currently no consensus on the critical telomere length of MSCs at 
senescence, and whether it would be applicable to different types of MSCs, different culture 
conditions and different telomere measuring methods. This renders the telomere length 
measurement method not a definitive method for measuring MSC senescence.  
Further problems of this method include that it cannot detect short telomeres that are 
present on a small number of chromosomes. As TRF reports an average of the lengths of 
telomeres, it does not provide information regarding single telomeres, this creates a 
significant limitation [66]. Polymerase chain reaction (PCR)-based telomere length analysis 
was developed to overcome the need for large quantities of DNA to evaluate telomere length 
[68], however, even when performed by experts, the PCR-based method results in variations 
due to differences in the method used for genomic DNA extraction, thus limiting its utility 
[66]. Notably, these methods are currently not suitable for measuring critical telomere length 
at senescence (i.e. identification of senescent cells) at the single-cell level. 
To counter this, researchers have proposed assays that can detect the length of specific, 
individual telomeres to overcome the shortcomings of TRF and PCR-based assays that only 
provide measures of the average telomere length of the specimen. Baird et al. adapted the 
qPCR-based method to provide single telomere length analysis (STELA) [69]. Further 
adaptation of the STELA method is known as Universal STELA that allows for the detection 
of any critically short telomere, regardless of the chromosomal location [70, 71]. Although 
these methods provide insight regarding individual telomere lengths, they are technically 
challenging and are sensitive to the amount of template DNA. In conclusion, even with an 
eventual agreement on the critical telomere length of senescent MSCs, such methods remain 
destructive, labour-intensive and time-consuming (Table 1), and therefore are unlikely to be 
adopted as first-line quality-control assay for measuring senescent cells in MSC cultures.  
 
Gene Expression Markers 
MSCs isolated from different tissue sources, or the same tissue from different donors exhibit 
significantly different cellular behaviour [72]. Especially for MSCs derived from different 
tissue sources, the gene-expression profile and trilineage differentiation outcomes vary 
greatly [73]. Nevertheless, some common genes characteristic for cell cycle arrest at late 
passages may be applicable to all MSC tissue sources. Amongst those are cell cycle inhibitors 
p16INK4A and p21[74], and measuring these molecules at the transcript level is commonly 
utilised to characterise senescent passages of MSCs [2, 67, 75]. In the study carried out by 
Feng et al., MSCs derived from human dental pulp (DP-MSCs) showed characteristics of 
senescence as a function of donor age [76]. Their results indicated that DNA damage 
response and stress response may be the main contributors of DP-MSCs senescence induced 
by excessive activation of p16INK4A signalling, and that the dysfunction of DP-MSCs could be 
reversed by p16(INK4A) siRNA. 
There are a number of other genes which could be indicative of MSC senescent passages. 
Wagner et al. have reported genes down-regulated during MSC replicative senescence 
including HSA1, ID1 and TNFSF11 [15]. In a more recent study by Churchman et al., the 
reduced expression of NANOG, TWIST1 and WIF1 in senescent MSC passages was found, as 
well as an increased expression of SPARC [17]. The decline in the NANOG, TWIST1 and 
WIF1 was proposed to indicate the loss of MSC multipotency during extended cultivation 
[77], and the steadily decline in the expression levels of CEBPA and FABP4 indicated the 
loss of their adipogenic potential [17].  
In another study, Bellayr et al. evaluated predictive gene markers of aged human bone 
marrow-derived MSCs using a two-colour gene expression microarray. Overall, 81 genes 
were identified to be significantly different between passages 3 and 7 of the hMSCs cells 
studied. From their cell proliferation essay results, MSCs also demonstrated a greater 
potential for cell division at passage 3 than passage 7 [78]. Ten of the differentially expressed 
gene markers Bellayr et al. have identified (BST1, COL11A1, COL12A1, GALNT5, HAS1, 
KRT18, MEG3, PCM1, PENK, and SHB) were identical to those reported in the earlier gene 
marker study by Kulterer et al. [79]. Furthermore, two of the gene markers identified in 
%HOODU\¶VVWXG\KRT18 and PRDX4, matched with those reported by Tanabe et al. [80] as 
well. Among these markers, Keratin KRT18 is the structural protein with a functional role in 
the stability of epithelial tissue [81], and for which significant gene expression changes were 
also reported in previous publications [80, 82].  
From these results, there appears to be an emerging consensus on certain gene markers that 
can be used in combination to characterise senescent passages of cultured MSCs [78], 
however these markers are measured at the cell population rather than at the single-cell level. 
Although the gene marker method might be useful for rapid prediction of MSCs quality and 
cellular aging over consecutive passaging in culture, it is technically difficult and expensive, 
and therefore unlikely to be suitable for routine quantification of senescent cells in MSC 
cultures.  
 
Gene Methylation and Epigenetic Markers 
Epigenetic modifications play a central role in differentiation and development, and DNA 
methylation is the best characterized epigenetic modification [83]. In 2007, Shibata et al. 
proposed that the methylation state of the p16INK4A gene, a cyclin-dependent kinase inhibitor, 
could be monitored against the replicative senescence of MSCs during in vitro expansion 
[84]. 
Histone deacetylases (HDACs) are a class of enzymes that catalyse the removal of acetyl 
JURXSVIURPİ-amino group of lysine residues in the histone tail [2]. During the progression 
of MSC senescence, HDAC inhibitors were found to downregulate polycomb group genes, 
and DNA methylation status of MSCs is proposed as another method for monitoring the gene 
expression of aging MSCs [2]. Gene expression can be regulated by DNA methylation 
through interference with transcription factors or methyl-CpG binding proteins, leading to 
silencing of respective promoter regions [85]. Koch et al. have studied the correlation 
between cellular senescence and DNA-methylation at specific CpG sites using human 
fibroblasts and MSCs from bone marrow [86]. Analysis of DNA-methylation level at six 
CpG sites allowed reliable estimates of passage number in fibroblasts and MSCs, and the 
continuous changes in DNA-methylation in specific CpG sites were suggested as a marker to 
predict the state of cellular senescence of cultured MSCs [86]. Churchman et al. have also 
confirmed that the methylation of CpG islands had very strong associations with PD [17].  
    miRNA are non-coding RNAs of approximately 22 nucleotides in length that exert a post-
transcriptional effect on gene expression, which are also epigenetic regulation markers [87]. 
Wagner et al. analysed the role of miRNA expression in determining MSC senescence on the 
molecular level and demonstrated that certain miRNAs (hsa-mir-371, hsa-mir-369-5P, hsa-
mir-29c, hsa-mir-499 and hsa-let-7f) are up-regulated upon MSC replicative senescence [15]. 
They also showed that mir-29c directly targets DNA-methyl transferase 3A (DNMT3A) and 
3B (DNMT3B) both of which are involved in cell proliferation and epigenetic regulation 
[15], and thus suggesting that senescence associated up-regulation of these miRNAs results in 
changes in the methylation pattern of proliferation inducing genes [15]. 
The primary drawback of measuring methylation as an indicator of senescence, similar to 
gene expression markers, is that it can only be performed at the cell culture level. It is 
important to note that gene specific methylation may be tissue-specific, and the genes of 
interest increase along with the number of tissues of relevance, which cause the method to be 
time-consuming and very costly [17, 88].  
 
Promising New Methods 
Although evaluating SA-E-gal activity to detect cell senescence is widely adopted across 
laboratories, the limitations of SA-E-gal method such as dependence on the state of cell 
confluence has been reported [89, 90] and alternative methods to measure MSC senescence, 
particularly at the singe-cell level have been developed [84]. Particularly for MSCs, it is 
important to consider from the outset how amendable these new methods would be for 
different types of scalable MSC manufacture approaches. For example, dynamic-culture 
bioreactors or planar-culture µFHOOIDFWRULHV¶ [91-94], which may ultimately dictate the method 
employed. So far, the senescence status of MSCs grown on microcarriers in bioreactors 
continues to be assessed off-line [22] following MSC harvesting, plating in 2D and SA-E-gal 
activity staining in monolayer conditions [95]. Off-line here refers to monitoring by sampling 
a small volume of the cell culture for further analysis, either beside or away from the 
manufacturing line. Comparatively, on-line methods require no sampling and provide real-
WLPHLQIRUPDWLRQRIWKHFHOOV¶HQYLURQPHQt [22]. 
 
Prelamin A staining 
Recent studies have revealed a correlation between accumulation of prelamin A and cellular 
aging [96, 97]. Progeria, a disease with symptoms of premature ageing and an average life 
span of 13 years, is resulted by heterozygous mutation in LMNA gene, and the affected 
protein cannot function correctly to mature lamin A [98]. Lamin A is a key structural 
component of the nuclear lamina, and is generated from a precursor protein, prelamin A [99]. 
Alteration to the nuclear lamina, a filamentous meshwork involved in regulation of the inner 
nuclear membrane and chromosomes, is recognised as a change associated with aging cells. 
ZMPSTE24, a membrane zinc metalloproteinase [100], downregulated by in vitro aging in 
MSCs induces the upregulation of prelamin A, which leads to the induction of abnormal 
nuclear morphology and DNA damage [96]. Bellotti et al. have recently demonstrated that 
prolonged in vitro culture of human MSCs triggered replicative senescence and simultaneous 
accumulation of prelamin A, as measured by immunostaining for the full-length form of the 
lamin A precursor [101]. In another study utilising human skin fibroblasts, the oxidative 
stress- and replicative senescence was shown to affect prelamin A processing through the 
reduction of ZMPSTE24 expression [102]. Based on other previous reports showing that the 
accumulation of precursor of prelamin A induces molecular changes in MSCs such as 
multilineage differentiation [96], the group suggested that prelamin A accumulation could be 
used as a marker for detecting senescent MSCs in prolonged culture.  
 
Cell surface proteins 
Moravcikova et al. have recently used a high-throughput cell surface proteomic approach to 
analyse the changes in cell surface protein expression of CD45-/CD31-/CD34-
/CD73+/CD105+ stromal cells in unpassaged BM MSC and subsequently determine the 
changes in cell surface markers with accompanying passage [103]. The group presented that 
the adhesion molecule CD106/VCAM1 is highly expressed in unpassaged MSC but 
decreases drastically with culture. This confirmed previous studies including ours [53, 104], 
however other studies showed increased CD106 expression [105], or random oscillation with 
passaging [106]. Similar controversy remains in relation to CD146 expression on in vitro 
aged MSCs [53, 104, 106].  
Also for migration of MSCs, a metalloprotease associated with cell motility, 
CD10/neprilysin, has been shown to be rapidly upregulated in culture but decreased with 
early senescence [103]. Whereas no consensus yet exists in relation to a specific expression 
of classical MSC surface molecules on senescent MSCs, recent studies have identified new 
molecules such as cell surface protein DPP4 and membrane-bound vimentin to identify 
senescent cells [107, 108]. These studies were carried out using a combination of methods 
including mass spectrometry, flow cytometry and functional in vitro and in vivo assays.  
Having been confirmed by other independent studies, these new surface markers of senescent 
cells can be combined, in theory, with flow cytometry-based measurements of SA-E-gal 
activity and cell size, as well as be targeted for novel antibody-based senolytic approaches.  
 
Cell surface lipids 
Another recently proposed potentially flow cytometry-compatible method for measuring 
senescent cells in cultures and tissue samples is based on a histochemical staining of their 
lipofuscin content [109]. In senescent cells, aggregates of oxidized proteins, metals and lipids 
accumulate as lipofuscin. Although lipofuscins are auto-fluorescent, as further elaborated in 
the subsequent section, this fluorescence is very weak. Georgakopoulo et al. have utilized in 
their method a staining technique to enhance the detection of lipofuscin [109]. Of note, all the 
above methods still require a small sample of MSC culture to be sacrificed for the analysis, 
therefore remain destructive. In addition, their need for staining or fluorescent tags makes 
them non-label-free. 
Another attractive option is cell plasma membrane lipid composition analysis that can be 
performed using tangential flow filtration [110-112].  It capitalises on the fact that plasma 
membranes of senescent cells become more rigid compared to their non-senescent analogues. 
While this biophysical method still requires some cells to be removed for the analysis, it 
being label-free leads to a reduction in the time required and cost of the assay. 
     
Measurements of cell size 
Cell enlargement is a key characteristic of senescent cells in culture [15, 67, 113], and as 
recently shown, possibly in vivo [75]. In the study by Biran et al., the authors utilized flow 
cytometry technology combined with high content image analysis to quantify DNA damage-
induced senescent human fibroblasts in culture [75]. In their technique, they employed 
ImageStream X, an advance imaging flow cytometer capable of producing high resolution 
bright field and fluorescent images of individual cells. Prior to flow cytometry analysis they 
stained senescent fibroblasts for SA-E-gal activity and therefore, were able to correlate SA-E-
galactosidase staining and the cell size, as well as other markers of cell proliferation and 
senescence such as Ki67 and HMGB1. Their results clearly showed a possibility of 
combining flow cytometry-based SA-E-gal measurements with the cell size analysis for the 
same sample of cells. The applicability of such methods for human MSCs has been recently 
shown in Bertolo et al. where SA-E-galactosidase activity in BM-MSCs was assessed using 
both chromogenic and fluorescent substrates and correlated with cell size and granularity 
[63]. 
    Another recent study by Oja et al. analysing MSC cell size, has utilised live cell  imaging 
analysis and reported that cell morphology and size could be a useful tool for evaluating the 
aging process and approaching senescence in cultured MSCs [67]. They suggested that cell 
area could be the most statistically significant and practical parameter for representing 
morphological changes that correlate with biochemical and gene expression markers of 
senescent cells. In their study, MSCs from passage 1 and 3 were uniform in size with around 
1800 to 2500 µm2 in cell area. Cells began to enlarge after passage 5 and resulted in a 4.8-
fold increase in cell area at passage 6-9 as compared to passage 1. Other senescent markers 
such as the expression of p16INK4a and activity of E-galactosidase were reported to have a 
strong correlation with the increase in cell area [67]. With the cell size analysis methods, 
however, there is still a lack of a consensus on the critical cell size for senescent MSCs, and 
whether cell size is influenced by tissue source and culture conditions.  
     The way MSC cell size is measured ± in growing cultures or on MSCs in suspension - 
needs to be evaluated and eventually, standardised. MSCs cultured in 2D conditions have the 
advantage of being non-destructively imaged for cell size analysis. However, such imaging 
modalities fail to perform for MSCs grown within microcarrier beads in bioreactors, as the 
beads interfere with imaging and also affect MSC spreading and shape depending on the 
beads being used. This make on-line cell size analysis challenging, therefore conducting off-
line MSC cell size measurements post-harvesting is likely be more widely adopted in a near 
future. Measuring MSC size in suspension by flow cytometry, in combination with 
fluorescence-based assessment of SA-E-gal activity [63, 75] represents an attractive option. 
Other label-free methods to identify and sort MSC subpopulations involve using 
microfluidics, where channels of micron-meter dimension are employed to sort cells in a 
high-throughput manner. For example, using a microfluidic method Yin et al. found that 
large cell populations (average cell size around 23-25 µm) expressed higher level of 
VHQHVFHQFHDVVRFLDWHGȕ-galactosidase as compared to smaller cell populations (average cell 
size of 11-12 µm) [114].  
 
Autofluorescence measurements 
Another recently explored label-free and non-destructive method utilizes native biomarkers. 
Native biomarkers offer insights into the biochemistry of cells without the need for 
fluorescent labels or stains. Endogenous fluorophores are one such class of biomarkers and 
are responsible for autofluorescence in cells. Autofluorescence has found many applications 
in biomedical research and diagnosis [115], with lipofuscins being an indicator of cell 
senescence [116], as mentioned above. Fluorescence from lipofuscins have been 
demonstrated as feasible senescence indicators via conventional methods of fluorescence 
microscopy [117] and spectroscopy [118]. In these studies, autofluorescence intensities were 
observed to increase with increasing cell senescence in rat fibroblasts and neonatal rat cardiac 
myocytes respectively. Lipofuscin autofluorescence has similarly been probed in flow 
cytometry for HeLa cells [119]. Most recently, cell autofluorescence measured on a 
FRQYHQWLRQDOIORZF\WRPHWHUZDVSURSRVHGWREHµDUeliable in vitro marker of cellular 
senescence in human MSCs [63]¶ although this interesting study is awaiting validation by 
other groups. 
    Despite the label-free and non-destructive advantage when using lipofusin fluorescence for 
cell senescence, there is still the challenge in acquiring autofluorescence due to its weak 
intensities. A potential workaround to this was recently explored in the method of cell lasing 
using endogenous fluorophores [120]. Through lasing, weak autofluorescence could 
potentially be amplified for easier detection.  
 
Raman Scattering  
Aside from autofluorescence, Raman scattering is another native signal from cells that does 
not require any labels. Raman spectroscopy has likewise been investigated for its ability in 
distinguishing between young and senescent cells. This was demonstrated in breast cancer 
cells [121], human umbilical cord MSCs [122] and in human dermal fibroblasts [123, 124]. 
In Raman spectroscopy, the Raman peaks provide biochemical and compositional 
information of the probed cells. Changes in intensities and spectral positions of these peaks 
thus correspond to changes in cells. However, like when using autofluorescence, Raman 
scattering has its drawbacks. In particular, changes in Raman peaks are typically too subtle 
for easy identification. In that regard, of note is the incorporation of machine learning 
methods in the more recent publications [123, 124] that largely facilitate the data analysis 
process.  
 
 
Imaging and other label-free methods 
More advanced optical techniques have also been reported to be capable of identifying 
senescent cells. These include light-sheet [125, 126] and digital holographic cytometry [127], 
methods which probe the biophysical aspects of cells to determine senescence. In particular, 
light-sheet cytometry uses the different scattering patterns of cells to determine their 
respective sizes and in turn senescence levels. On the other hand, digital holography 
cytometry essentially captures 3D images of cells and passes it through software for feature 
extraction. Apart from cell size and area, digital holography cytometry can generate 
information on cells¶ height, rates of division, motility and migration directionality. It is 
worth noting here that such acquisitions involve large amounts of data, typically 
incomprehensible by humans, therefore the involvement of machine learning and artificial 
neural nets has steadily gained popularity and importance in such technologies.  
This is because the accuracy of cell counting based on images is critically dependent on 
image segmentation. Conventional computer vision methodologies achieve segmentation 
through classical image processing methods like filtering, intensity thresholding and feature 
detection. The typically reported challenges of applying such methods in live cell imaging 
pertain to segmentation accuracy; the consequent time required to separate accurately and 
inaccurately segmented images, as well as robustness across cell types and human operators 
[128]. Machine learning methods ease these challenges by automating segmentation and 
facilitating classification [129]. Deep learning, a category of machine learning, has recently 
shown exceptional performance in this area by offering the advantage of independently 
learning key features. It has been successfully applied in microscopy images of cells using 
various deep learning methods like deep convolution neural networks [130] and autoencoders 
[131].  
Apart from segmentation for cell counting, machine learning methods have also been 
specifically applied in morphological profiling for identification of MSC subpopulations 
[132]. Finally, machine learning has also recently been explored for the discovery of CQAs 
that are to be assessed during the manufacture of stem cell-derived cell therapy products 
[133]. With tools like deep learning-based cell counting [134] being made freely available to 
the community, it is expected to see wide-spread applications in the MSC cell therapy area in 
the coming years. 
The only example of non-destructive and label-free technology is a method recently 
reported by Tomita et al., where the authors detailed a non-invasive method for in vitro 
characterization of cell senescence in human fibroblasts based on their overall SASP profile 
of culture supernatants [135]. The authors suggested that their newly-developed polyion 
complex array allowed noninvasive tracking and early detection of replicative senescence 
progress even when a conventional marker such as SA-ȕ-galactosidase indicates negative. 
This is awaiting an independent investigation but remains a very attractive possibility for on-
line assessment of MSC senescence. Of note, such a method does reflect the state of MSC 
senescence at the population level, but still does not quantify individual senescent cells. 
Furthermore, the composition of the SASP appears to vary depending on the cell type from 
which senescent cells originated and how senescence was induced [136], this should be 
accounted for in future translational development of this assay. 
 
Outlook and Future Directions 
Based on the literature presented in this review, it can be proposed that methodologies 
allowing identification and quantification of senescent cells in therapeutic MSC batches 
would be advantageous for the MSC cell therapy field. When measured at cell culture level, a 
cut-off point can be developed, beyond which the cells could be considered unacceptably 
high in senescent cell burden, and hence therapeutically unsuitable. Such a test may represent 
one of the CQAs of manufactured MSC batches [21, 23]. 
Something even more advantageous would be having a method capable of identifying 
individual senescent cells particularly for autologous applications, where only small numbers 
of donor MSCs are available for expansion. In these situations, a FXOWXUHV¶VHQHVFHQWFHOOVFDQ 
be targeted for removal using current or new-generation senolytics [136]. Currently used 
senolytics, such as dasatinib and quercetin, target the Senescent Cell Anti-apoptotic Pathways 
based on the observation that senescent cells are resistant to apoptosis [136]. However 
classical senolytic agents may not always be very effective, as shown in a recent study [137]. 
Specific senescent cell surface markers as described in Kim et al. [108] may be more useful 
for not only to detect but also to selectively eliminate senescent cells using monoclonal 
antibodies conjugated to magnetic beads, or other cell separation technologies [138]. In large-
scale MSC manufacturing processes, senescent cell removal can be performed during 
downstream processing stage [139], for example, as a part of cell harvesting, washing or cell 
concentration stages. 
    Amongst the standard PHWKRGVȕ-galactosidase based measurements are likely to stay for 
at least the next handful of years. As presented in this review, this method is capable of 
identifying individual senescent cells, and is already undergoing refinements in order to be 
combined with cell size measurements and high-throughput technologies such as flow 
cytometry or automated image analysis. Although the method remains destructive and not 
label-free, it currently serves as a positive control for other methods being developed, and as 
such is likely to continue to be in use for the near future.  
    The current consensus in the field of senescent cell biomarkers appears to be the use of 
multiple-marker signatures [111, 136]. As described above, biophysical-based cell 
characterisation methods offer the advantage of being label-free, while methods paired with 
flow cytometry allow for analysis of individual cells. Therefore, the best way forward may be 
a combination of methods involving cell size and label-free spectroscopic measurements 
since the combination has potential of being entirely non-destructive. Although such methods 
are not readily implementable for on-line monitoring at this point in time, they could still be 
particularly useful for rapid assessment of senescent cell numbers throughout the different 
stages of the manufacturing process. This is in contrast to conventional standards that take a 
long time and also irreversibly modify or even destroy the cells during examination, 
inevitably reducing the available number of MSCs for downstream processes. Furthermore, 
the combination of cell size and label-free spectroscopic measurements can be high 
throughput and thus time efficient with maximum output of the final therapeutic-grade MSC 
product. It should however be highlighted that spectroscopic measurements always require 
some form of excitation light. This could potentially pose the issue of photodamage of cells, 
which typically comes with prolonged exposure to light. Additionally, the limited reach of 
light into and out of non-homogenous mixtures like cell cultures, could restrict measurements 
to just a single-layer. These factors would definitely have to be considered in the 
development of on-line methods for characterizing senescent cells following large-scale MSC 
manufacture in multi-layer culture vessels or on beads in bioreactors [140, 141].  
     Apart from characterising clinical-JUDGH06&EDWFKHVIRUSRWHQWLDOµVHQHVcent cell 
EXUGHQ¶new culture conditions limiting MSC senescence should continue to be developed 
(Table 2). Historically, culturing MSCs in hypoxic conditions, without or with the addition of 
growth factors such as fibroblast growth factor, has prolonged the onset of senescence in 
MSCs. More recently, a better understanding of the effects of hypoxia, and the mechanisms 
of oxidative stress-induced MSC senescence has contributed to the development of new 
supplements to the culture media that improve MSC expansion with delaying senescence. For 
example, Antonioli et al. have recently reported that the addition of rapamycin (an inhibitor 
of the mTOR signaling pathway) to bone marrow MSC cultures delayed their senescence as 
evident by the diminished secretion of IL6 and elevated expression of NANOG gene, and this 
effect was associated with p16INK4A protein downregulation [142]. In another study, the 
supplementation of MSCs with nicotinamide (a precursor of NAD+ that has been shown to 
reduce ROS generation) noticeably extended their replicative life span with a significant 
postponement in the onset of senescence [143]. Recent studies treating animal MSCs with 
ascorbic acid, or with an antioxidant cytokine C1q and tumor necrosis factor related protein 9 
(CTRP9) [144], have also shown promise and need to be tested on human MSCs. In terms of 
selecting MSC tissue source for expansion, apart from tissue¶V propensity for certain lineage 
differentiation or trophic factor secretion, greater consideration should be given to MSC 
oxidative stress resistance [145] and desirably, longer onset of senescence. Even amongst 
perinatal cells, known to reach senescence later than adult tissue-MSCs [146], tissue specific 
differences exist, as shown recently in Kwon et al. study [147].  
    Finally, for cell therapy success, host tissue pathology and cell delivery considerations 
should be taken into account early in product manufacture (µEHJLQQLQJZLWKWKHHQGLQPLQG¶ 
or Quality by Design [23] concept). For example, for delivering MSCs into the joints and 
other hypoxic environments, their resistance to hypoxia may be a highly desirable feature to 
be tested and ultimately, quality-controlled. Overall, a holistic approach taking into 
consideration both cell therapy and host factors is currently needed to achieve a more rapid 
uptake of MSC cell therapies into the clinic. Predictive software algorithms and new machine 
learning technologies should be on the forefront of this endeavour. 
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Method Parameters 
Measured 
Method 
Description 
Single-
cell or 
Cell 
populatio
n Level  
Off-line 
only or 
Potential 
for on-line 
monitoring 
Experime
nt Time 
Destructive or Non-
destructive 
Labelled/Label-
free 
Type of Cell 
Tested 
SA-E-gal 
measurements 
 
E-gal activity Cytochemical or 
fluorescent 
detection of SA-
E-gal activity 
through staining 
or flow 
cytometry 
Both Off-line 
only 
Less than 
1 day 
Destructive, requires a 
small sample of 
growing cells 
Chromogenic or 
fluorescent 
substrate  
Human diploid 
fibroblast-like 
cells[59] 
BM-MSC[15] 
Human 
fibroblast[58, 61]  
Telomere 
length 
measurements 
 
Critically 
short 
telomere 
length 
Various: Mean 
telomere 
restriction 
fragment 
(mTRF); PCR-
based telomere 
length analysis; 
Single telomere 
length analysis 
(STELA); 
Universal 
STELA 
Method-
dependent 
 
 
Off-line 
only 
Up to a 
week 
Destructive, requires a 
sample of growing 
cells 
End-labelling of 
telomeric 
oligonucleotide  
BM-MSC[43, 67] 
Skin fibroblast 
cell[69, 70] 
 
Gene 
expression 
markers 
 
Gene 
expression  
Candidate gene-
expression 
measurements 
or profiling by 
microarray 
technology  
Method-
dependent 
Off-line 
only 
Up to a 
week for 
a small 
number of 
genes 
Destructive, requires a  
sample of growing 
cells 
cDNA labelling BM-MSC [17, 73, 78-
80] 
DP-MSCs[76] 
Human dermal 
and lung 
fibroblasts[77] 
Gene 
methylation 
and other 
epigenetic 
markers 
 
 miRNAs, CpG 
sites with either 
linear increase 
or decrease in 
the methylation 
levels 
Culture Off-line 
only 
Up to a 
week for 
a small 
number of  
candidate
s 
Destructive, requires a  
sample of growing 
cells 
DNA labelling Human fibroblast 
cells[86] 
BM-MSC [2, 15, 17, 
86]
 
Adipose tissue 
mesenchymal 
stromal cells [86] 
Prelamin A 
staining 
 
 
 
Lamin A Confocal 
imaging of 
prelamin A 
nuclear 
distribution 
following 
immunostaining 
Both Off-line 
only 
Less than 
1 day 
Destructive, requires a  
sample of growing 
cells 
Antibody 
labelling 
BM-MSC[101] 
Cell surface 
proteins  
 
Various cell 
surface 
protein 
expression 
Cell surface 
proteomic 
approach to 
analyse the 
changes in cell 
surface protein 
expression 
Both Off-line 
only 
Less than 
1 day 
Destructive, requires a  
sample of growing 
cells 
Antibody  
labelling  
BM-MSC [53, 103, 
104, 106] 
Human diploid 
fibroblast cells 
[107] 
Mouse lung 
fibroblasts [108] 
Cell size 
measurements 
 
Cell size Cell images 
acquired by 
high-content 
screening 
microscopy or 
flow cytometry  
Both Potential 
for on-line 
monitoring 
Less than 
1 day 
Currently destructive 
but can be modified 
for growing cells 
adherent to culture 
vessels 
Histochemical 
staining but can 
be applied to 
holographic 
cytometry  
BM-MSC[15, 67] 
Human 
fibroblasts[75] 
Cell auto-
fluorescence 
measurements 
Lipofuscins  Conventional 
methods of 
microscopy and 
spectroscopy 
Both Potential 
for on-line 
monitoring 
Few 
minutes 
to hours 
(dependin
g on 
number of 
runs ± 
each 
measurem
ent takes 
<1min) 
Non-destructive Label-free Rat fibroblasts[118] 
Neonatal rat 
cardiac 
myocytes[117] 
HeLa cells[119] 
Cell Raman 
scattering 
measurements 
Various 
biochemicals 
in cells 
(presented as 
Raman 
peaks) 
Conventional 
Raman 
spectroscopy or 
microspectrosco
py.  
Both Potential 
for on-line 
monitoring 
Few 
minutes 
to hours 
(dependin
g on 
number of 
runs ± 
each 
measurem
ent takes 
<1min) 
Non-destructive Label-free Breast cancer 
cells[121] 
Human umbilical 
cord MSCs[122] 
Human dermal 
fibroblasts[123, 124] 
 
Table 1. Current standards and new methods for characterizing senescent MSC passages or senescent cells in cultures. 
  
Table 2: Methods to minimize MSC senescence during expansion  
 
 
 
Method category The method Mechanisms of action 
Genetic modification - 
telomere based 
 
Transduction by a retroviral vector 
containing the gene of human 
telomerase (hTERT)  [148] 
Increases MSC lifespan via telomere 
length preservation 
Hypoxia Culturing MSC in low oxygen 
conditions [149-151] 
Reduces MSC oxidative stress and 
modifies cell metabolism; prevents the 
induction of p53 expression and 
mitochondrial ROS levels[152] 
 
Helps an induction of transcripts 
associated with HIFͲĮ 
 
Hypoxia combined with 
growth factor 
supplementation or 
genetic manipulation 
Hypoxia + fibroblast growth factor 
(FGF)  
Increases MSC proliferation partially 
via ERK signalling pathway and HIF-
ĮH[SUHVVLRQHQKDQFHPHQW[153] 
Hypoxia + Insulin-like growth factor-
1 (IGF-1) knockdown  
Increases autophagy of aged MSCs via 
decreased the activity of the Akt/mTOR 
signalling[154] 
Genetic modification Over-expression of Neuron-Derived 
Neurotrophic Factor (NDNF)  
Enhances MSC proliferation and 
survival via increased Sirtuin 1 
expression [155] 
Over-expression of Sirtuin 1  Regulates p53/p21 pathway [156] 
Media supplements Rapamycin  p16INK4A protein downregulation [157] 
Hybrid complexes of high and low 
molecular weight hyaluronan {Alessio, 
2018 #176}  
 
Unclear mechanism 
Nicotinamide (NAM) 
 
Activation of autophagy through 
Sirtuin mobilization [143, 156, 158] 
Ascorbic acid  Reduction in ROS levels and inhibition 
of the AKT/mTOR signalling[159] 
C1q and tumour necrosis 
factor-related protein 9 (CTRP9)  
 
Reduction in ROS levels and induction 
in superoxide dismutase (SOD) activity 
response[144] 
